pNaKtide inhibits Na/K-ATPase reactive oxygen species amplification and attenuates adipogenesis by Sodhi, Komal et al.
Marshall University
Marshall Digital Scholar
Biochemistry and Microbiology Faculty Research
Fall 10-16-2015
pNaKtide inhibits Na/K-ATPase reactive oxygen
species amplification and attenuates adipogenesis
Komal Sodhi
Marshall University, sodhi@marshall.edu
Kyle Maxwell
Yanling Yan
Marshall University, yan@marshall.edu
Jiang Liu
Marshall University, liuj@marshall.edu
Muhammad Chaudhry
Marshall University, chaudhry@marshall.edu
See next page for additional authors
Follow this and additional works at: http://mds.marshall.edu/sm_bm
Part of the Medical Biochemistry Commons, Medical Microbiology Commons, Medical
Specialties Commons, and the Other Medical Sciences Commons
This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Biochemistry and Microbiology by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu, martj@marshall.edu.
Recommended Citation
Sodhi K, Maxwell K, Yan Y, Liu J, Chaudhry MA, Getty M, Xie Z, Abraham NG, Shapiro JI. pNaKtide inhibits Na/K-ATPase reactive
oxygen species amplification and attenuates adipogeneses. Science Advances. 2015;1(9), e1500781
Authors
Komal Sodhi, Kyle Maxwell, Yanling Yan, Jiang Liu, Muhammad Chaudhry, Morgan Getty, Zijian Xie, Nader
G. Abraham, and Joseph I. Shapiro MD
This article is available at Marshall Digital Scholar: http://mds.marshall.edu/sm_bm/178
B IOCHEM ISTRY 2015 © The Authors, some rights reserved;
exclusive licensee American Association for
the Advancement of Science. Distributed
under a Creative Commons Attribution
NonCommercial License 4.0 (CC BY-NC).
10.1126/sciadv.1500781
pNaKtide inhibits Na/K-ATPase reactive
oxygen species amplification and
attenuates adipogenesis
Komal Sodhi,1 Kyle Maxwell,1 Yanling Yan,1 Jiang Liu,1 Muhammad A. Chaudhry,1 Morghan Getty,1 Zijian Xie,1
Nader G. Abraham,1,2 Joseph I. Shapiro1*
Obesity has become a worldwide epidemic and is a major risk factor for metabolic syndrome. Oxidative stress is
known to play a role in the generation and maintenance of an obesity phenotype in both isolated adipocytes and
intact animals. Because we had identified that the Na/K-ATPase can amplify oxidant signaling, we speculated that a
peptide designed to inhibit this pathway, pNaKtide, might ameliorate an obesity phenotype. To test this hypothesis,
we first performed studies in isolated murine preadipocytes (3T3L1 cells) and found that pNaKtide attenuated
oxidant stress and lipid accumulation in a dose-dependent manner. Complementary experiments in C57Bl6 mice
fed a high-fat diet corroborated our in vitro observations. Administration of pNaKtide in these mice reduced body
weight gain, restored systemic redox and inflammatory milieu, and, crucially, improved insulin sensitivity. Thus, we
propose that inhibition of Na/K-ATPase amplification of oxidative stress may ultimately be a novel way to combat
obesity, insulin resistance, and metabolic syndrome.
INTRODUCTION
The number of overweight individuals worldwide has markedly grown,
leading to an increase in obesity-related health problems and associated
morbidity and mortality (1). Oxidative stress in adipose tissue is an im-
portant pathogenic mechanism leading to maintenance of the obesity
phenotype–associated metabolic syndrome (2–5). It has recently been
observed that the development of obesity can be markedly affected by
the manipulation of either the systemic redox state (6–11) or the redox
state of adipocytes alone (2, 12). Specifically, manipulation of the redox
state of adipocytes by the targeted transfection of antioxidant genes to
adipocytes alters their phenotype as well as reduces total body fat stores
and ameliorates metabolic abnormalities (13, 14).
Dysfunctional adipogenesis is one of the hallmarks of chronic obe-
sity and is characterized by increased lipid accumulation and altered
endocrine function of the adipose tissue (15). Peroxisome proliferator–
activated receptor g (PPARg) is a master regulator of adipogenesis and
activates the expression of genes, such as fatty acid synthase (FAS), to
trigger the synthesis of fatty acids and triglycerides (16). Mesoderm-
specific transcript (MEST), when up-regulated, results in adipocyte
enlargement during adipose tissue expansion (17), which is associated
with increased release of inflammatory adipocytokines and enhanced
insulin resistance (3). Adipose tissue regulates energy metabolism via
secretion of soluble factors such as adiponectin and tissue necrosis
factor–a (3). Dysregulated production of these adipocytokines partic-
ipates in the pathogenesis of obesity-associated metabolic syndrome
(3, 18–20).
The Na+- and K+-dependent adenosine triphosphatase (Na/K-ATPase)
is a member of the P-type ATPase family. It resides in the plasma
membrane and transports Na+ and K+ ions across the cell membrane
by hydrolyzing ATP. The functional Na/K-ATPase consists of a and b
subunits, and several isoforms have been identified for each subunit
(21, 22). Our group has observed that, in addition to the ion pumping
function, the a1 subunit also serves a scaffolding function with sarcoma-
related kinase (Src), allowing conformational changes in the Na/K-
ATPase to effect a signaling cascade. We have specifically identified a
NaKtide sequence from the nucleotide-binding (N) domain of this a
subunit, which binds the kinase domain of Src, tonically inhibiting its
function. However, when the conformation of the a1 subunit is changed
by the binding of cardiotonic steroids, this inhibition may be released,
resulting in the activation of Src (23–25). The Na/K-ATPase therefore
controls signaling by regulating Src through downstream modulation
of the epithelial growth factor receptor (EGFR) and ultimately reactive
oxygen species (ROS) (26, 27).We have recently observed that the a1 sub-
unit of the Na/K-ATPase can also act as a receptor for some ROS and
potentially serve as a feedforward amplifier (28, 29). Moreover, we have
designed a cell-permeant NaKtide (pNaKtide) and found it to specif-
ically inhibit cardiotonic steroid–induced Src activation (30–33). Given
the importance of the adipocyte redox state in the development and
maintenance of obesity, we reasoned that pNaKtide might significant-
ly attenuate Na/K-ATPase–modulated ROS amplification within the
adipocyte and attenuate the development of adiposity.
RESULTS
Effect of pNaKtide on adipogenesis in
murine preadipocytes
3T3L1 cells were exposed to adipogenic media (16, 34) and treated
with increasing doses of pNaKtide. Our results showed that pNaKtide
reduced lipid accumulation (Fig. 1) in 3T3L1 cells in a dose-dependent
manner. As a control, we exposed these cells to rhodamine-labeled
pNaKtide and found that pNaKtide readily passed the cell membrane
and resided in the intracellular membrane compartments (fig. S1A).
In addition to decreasing the net accumulation of lipid, pNaKtide also
increased the amount of lipid in small droplets while decreasing the
proportion in large droplets, also in a dose-dependent manner (fig. S2,
A and B, respectively). Oxidative stress is one of the consequences of
1Departments of Medicine, Pharmacology, and Surgery, Joan C. Edwards School of
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Na/K-ATPase activation. Superoxide levels, a marker for oxidative
stress, were significantly reduced by pNaKtide in 3T3L1 cells (fig.
S2C; P < 0.05). No cytotoxic effects of pNaKtide were noted at the
studied doses (up to 4 mM) (fig. S2D).
Effect of pNaKtide on adiponectin levels and adipogenic
markers in murine preadipocytes
Administration of pNaKtide increased adiponectin levels (Fig.2A;
P < 0.05), a known marker of small insulin-sensitive and healthy
adipocytes (35). Furthermore, our results showed that pNaKtide
treatment significantly reduced the expression of adipogenic markers,
including FAS, MEST, and PPARg (Fig. 2, B to D, respectively). Thus,
pNaKtide prevented adipocyte dysfunction, an effect that could be
attributed to its role in cellular redox through the Na/K-ATPase signal
cascade.
Fructose has been shown to induce oxidative stress and increase
adipogenesis in adipocytes exposed to adipogenic media (36). As shown
in fig. S3, the fructose-induced increase in adipogenesis was prevented
Fig. 1. Effect of increasing pNaKtide concentrations on adipogenesis in mouse preadipocytes. Adipogenesis was measured as the relative absorb-
ance of Oil Red O at day 7 after inducing adipogenesis as described in Materials and Methods. (A) Representative images. (B) Quantitative data expressed
as means ± SE, n = 7; *P < 0.05 versus control.
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by treatment with pNaKtide in 3T3L1 cells. Similarly, addition of glucose
oxidase to the adipogenic media also increased lipid accumulation
(fig. S4A) and the adipogenic markers FAS and MEST in 3T3L1 cells
(fig. S4, B and C), and this was significantly attenuated by concurrent
treatment with pNaKtide. Treatment with pNaKtide also decreased
protein carbonylation and blocked the Na/K-ATPase–regulated acti-
vation of Src and extracellular signal–regulated kinases 1 and 2
(ERK1/2) in 3T3L1 cells exposed to glucose oxidase (fig. S5, A to C,
respectively).
Effect of pNaKtide on body weight and visceral and
subcutaneous fat content in mice fed a high-fat diet
In our in vivo studies, C57Bl6 mice were exposed to a high-fat diet for
4 weeks and then given pNaKtide at different doses via intraperitoneal
injection, and the high-fat diet was continued for another 8 weeks. In
parallel experiments, rhodamine-labeled peptide was demonstrated to
accumulate in adipose tissue (fig. S1B). Administration of pNaKtide at
25 mg/kg intraperitoneally every 8 days markedly reduced adiposity
in these mice, with lower doses having less effects (Figs. 3 and 4).
Fig. 2. pNaKtide increased adiponectin levels and decreased adipogenic markers in 3T3L1 adipocytes. (A) Adiponectin levels were determined in
conditioned media obtained from 3T3L1 cells after treatment with pNaKtide for 7 days. Cells were treated with varying concentrations of pNaKtide, and
0.7 mM pNaKtide was determined to be the optimal concentration for increasing adiponectin levels. Results are means ± SE, n = 4; *P < 0.05 versus control
(CTR). (B to D) Expression of (B) FAS, (C) MEST, and (D) PPARg was determined by Western blot analysis in 3T3L1 cells after treatment with pNaKtide
(0.7 mM) for 7 days. Quantitative densitometric evaluation of protein ratios was done. Data are expressed as means ± SE, n = 6; *P < 0.05 versus control.
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However, more frequent administration of pNaKtide (25 mg/kg in-
traperitoneally every 2 days) induced some fluid retention (fig. S2).
Therefore, we focused our subsequent studies on the effects of the
administration of pNaKtide every 8 days on adipogenic markers and
metabolic profile.
Effect of pNaKtide on adipogenic markers and adiponectin
expression in mice fed a high-fat diet
Mice fed a high-fat diet exhibited an increase in FAS (Fig. 5A) and
MEST (Fig. 5B) gene expression in visceral adipose tissue compared
to the control group. Treatment with pNaKtide (25 mg/kg every 8 days)
significantly decreased FAS and MEST levels compared to mice fed a
high-fat diet. Further, our results showed that pNaKtide treatment
increased adiponectin levels in visceral adipose tissue compared to
mice fed a high-fat diet (Fig. 5C). These observations support our hy-
pothesis that pNaKtide not only reduces adipose tissue mass but also
promotes the development of healthier adipocytes, with adiponectin
levels comparable to those seen with regular diet.
Effect of pNaKtide onmetabolic profile inmice fed a high-fat diet
The insulin resistance phenotype in mice fed a high-fat diet was re-
versed by the administration of pNaKtide. This was characterized by
Fig. 3. Effect of increasing doses of pNaKtide on body weight in mice fed a high-fat diet. Treatment with pNaKtide at doses of 1 and 5 mg/kg did
not significantly reduce body weight in C57Bl6 mice fed a high-fat diet. However, administration of pNaKtide at 25 mg/kg every 8 days in mice fed a high-
fat diet for 8 weeks significantly reduced body weight as compared to high-fat diet–fed animals. There were no significant changes in food intake among
the groups. Results are means ± SE, n = 7 to 14 per group; *P < 0.05 versus control, #P < 0.05 versus high-fat diet.
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significant improvements in the HOMA-IR score (Fig. 6A), improved
glucose tolerance (Fig. 6B), attenuation of oxidative stress in visceral
adipose tissue (Fig. 6C), and significantly elevated levels of circulating
adiponectin in mice concurrently treated with the peptide (Fig. 6D).
The administration of pNaKtide also significantly attenuated high-fat
diet–induced protein carbonylation in visceral adipose tissue (Fig. 6E)
and the activation of c-Src and ERK1/2 in mice fed a high-fat diet (Fig.
6, F and G).
DISCUSSION
This study characterizes the therapeutic potential for conditions
associated with obesity and metabolic imbalance. Oxidative stress, a fre-
quent accompaniment of chronic pathologies, has long been impli-
cated in the pathogenesis of adiposity. A plethora of antioxidants have
shown promise in reversing this effect in in vitro studies, with few in
vivo successes. We have demonstrated in this report that pNaKtide
effectively reduces adiposity and restores metabolic homeostasis
by antagonizing Na/K-ATPase–mediated amplification of ROS
signaling.
We observed that, in murine preadipocytes, exposure to pNaKtide
attenuated oxidative stress as well as the accumulation of lipid and the
manifestations of an obesity phenotype in a dose-dependent manner
in response to either adipogenic media or exogenous administration of
oxidative stress mediators, fructose or glucose oxidase. This decrease
in adipogenesis in murine preadipocytes treated with pNaKtide was
associated with significantly decreased expression of adipogenic regu-
lators including PPARg and FAS along with increased production of
adiponectin levels. Thus, the Na/K-ATPase inhibitor prevents dysfunc-
tional adipogenesis, an effect that could be attributed to its effects on
cellular redox. Moving to an in vivo model of obesity induced by a
high-fat diet, we again observed that intraperitoneal administration
of pNaKtide attenuated the development of obesity and the develop-
ment of metabolic syndrome. pNaKtide treatment resulted in a signif-
icant reduction in weight gain complemented by attenuation of visceral
Fig. 4. Effect of increasing doses of pNaKtide on visceral and subcutaneous fat content in mice fed a high-fat diet. (A and B) C57Bl6 mice fed a
high-fat diet (HF) for 8 weeks were injected with pNaKtide at doses of 1, 5, and 25 mg/kg every 8 days. Administration of pNaKtide at 25 mg/kg in mice
fed a high-fat diet significantly reduced visceral (A) and subcutaneous (B) fat content as compared to high-fat diet–fed animals. Results are means ± SE,
n = 7 to 14 per group; *P < 0.05 versus control, #P < 0.05 versus high-fat diet.
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and subcutaneous fat content in mice fed a high-fat diet. Dysfunctional
adipocytes are associated with the development of insulin resistance
and hyperglycemia, and they favor a proinflammatory state (37). Se-
vere insulin resistance, systemic inflammation, and dysregulation of
protective adipokines characterize metabolic syndrome. Our results
showed that pNaKtide decreased oxidative stress and insulin resistance
with an increase in adiponectin levels. We further demonstrated
that the decrease in obesity was associated with changes in adipo-
genic proteins. Mice fed a high-fat diet and treated with pNaKtide
displayed decreased levels of MEST and FAS expression, further
demonstrating the pNaKtide-mediated abrogation of adiposity and
metabolic imbalance.
These observations are of potential interest for several reasons. First,
we have clearly demonstrated the ability of the Na/K-ATPase signal
cascade to amplify ROS involved in adipogenesis, a process not pre-
viously linked to cardiotonic steroids or the Na/K-ATPase signal cas-
cade. Although a novel, well-tolerated antiobesity agent would be a
welcome addition to our clinical armamentarium, much work is nec-
essary to bridge the gap between rodents and humans. However, per-
haps of greater importance, the concept that ROS amplification can
occur through this pathway suggests that the Na/K-ATPase may serve
as a potential therapeutic target in a number of conditions character-
ized by oxidative stress, which ultimately become maladaptive. Per-
haps because pNaKtide targets the amplification of oxidants rather
than a primary signal cascade, it could provide new approaches for
the treatment of obesity and metabolic syndrome. If safety is demon-
strated in human studies, the clinical use of pNaKtide might ultimately
be possible.
Fig. 5. Effect of increasing doses of pNaKtide on adipogenic markers and adiponectin expression in visceral adipose tissue in mice fed a high-
fat diet. (A and B) Western blot and densitometric analysis of adipogenic markers in visceral adipose tissue, FAS (A) and MEST (B). Results are means ± SE,
n = 7 per group; *P < 0.05 versus control, #P < 0.05 versus high-fat diet. Data are shown as mean band density normalized to b-actin. (C) Western blot and
densitometric analysis of adiponectin expression. Results are means ± SE, n = 7 per group; *P < 0.05 versus control, #P < 0.05 versus high-fat diet. Data are
shown as mean band density normalized to b-actin.
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MATERIALS AND METHODS
Experimental design for in vitro experiment
Frozen mouse preadipocytes (3T3L1) were resuspended in a a-minimal
essential medium (a-MEM) supplemented with 10% heat-inactivated
fetal bovine serum and 1% antibiotic/antimycotic solution. The cultures
were maintained at 37°C in a 5% CO2 incubator, and the medium was
changed after 48 hours and every 3 to 4 days thereafter. When the 3T3L1
cells were confluent, the cells were recovered by the addition of tryp-
sin. 3T3L1 cells (passages 2 to 3) were plated in 96- and 24-well plates
at a density of 10,000 cells/cm2 and cultured in a-MEM until 80% con-
fluence was achieved. The medium was replaced with adipogenic
medium, and the cells were cultured for an additional 7 days. Cells were
treated everyday with 0.1, 0.3, 0.5, 0.7, 1, 2, and 4 mM pNaKtide. After
7 days, the cells were stained with Oil Red O solution to analyze ad-
ipogenesis as previously described by Sodhi et al. (34).
Measurement of lipid droplet size
Cell size was measured using ImagePro Analyzer. The classification of
the size of lipid droplets was based on size by area (pixels) as described
previously by Burgess et al. (38).
Measurement of superoxide levels for in vitro experiment
3T3L1 adipocytes were cultured on 96-well plates until they achieved
about 70% confluence. After treatment with 0.1, 0.3, 0.5, 0.7,1, 2, and
4 mM pNaKtide for 72 hours, the cells were incubated with 10 mM
dihydroethidium for 30 min at 37°C. Fluorescence intensity was mea-
sured using a Perkin-Elmer luminescence spectrometer at excitation/
emission filters of 530/620 nm (39).
Experimental design for in vivo experiment
All animal studies were approved by the Marshall University Animal
Care and Use Committee in accordance with the National Institutes of
Fig. 6. Effect of increasing doses of pNaKtide on metabolic profile in mice fed a high-fat diet. (A) HOMA-IR. (B) Glucose tolerance test.
(C) Thiobarbituric acid–reactive substance (TBARS), a marker of oxidative injury, was measured in visceral adipose tissue. (D) Plasma adiponectin levels.
Results are means ± SE, n = 7 to 14 per group; *P < 0.05 versus control, #P < 0.05 versus high-fat diet. (E to G) Effect of pNaKtide on protein carbonylation
and phosphorylation of c-Src and ERK1/2 in fat tissue in mice fed a high-fat diet. (E) Protein carbonylation. (F) Phosphorylation of c-Src. (G) Phosphorylation
of ERK1/2. Results are means ± SE, n = 4 to 7 per group; **P < 0.01 versus control, #P < 0.01 versus high-fat diet.
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Health (NIH) Guide for the Care and Use of Laboratory Animals. C57Bl6
mice (6 to 8 weeks old, male) were purchased from The Jackson Lab-
oratory. Upon arrival to the Robert C. Byrd Biotechnology Science
Center Animal Resource Facility (ARF), the mice were placed in cages
and were fed normal chow diet and had access to water ad libitum.
The high-fat diet was commercially purchased from Bio-SERV. The
high-fat diet contained 58% fat from lard, 25.6% carbohydrate, and
16.4% protein yielding 23.4 kJ/g. After 4 weeks of the high-fat diet,
the animals were divided into four groups, and treatment was done
for 8 weeks as follows: pNaKtide (dissolved in saline and injected in-
traperitoneally) at doses of 0, 1, 5, and 25 mg/kg every 8 days. Body
weight was measured every week. At the end of the 12-week period,
the mice were subjected to an 8-hour fast and then anesthetized with
sodium pentobarbital (65 mg/kg, intraperitoneally); blood was ob-
tained from the tail vein for measurement of glucose with a gluc-
ometer and of insulin with an enzyme-linked immunosorbent assay
(ELISA) kit (Abcam). At the time of sacrifice, the body weight, visceral
and subcutaneous fat content, and liver weight of all mice were
measured. Blood samples were collected for determination of adipo-
nectin levels. Visceral adipose tissue was flash-frozen in liquid nitro-
gen and maintained at −80°C until assayed.
An additional group in which pNaKtide was administered at 25 mg/kg
intraperitoneally every 2 days (n = 7) was also studied. These animals
had less attenuation of weight gain than the group administered with
25 mg/kg intraperitoneally every 8 days, but at the time of sacrifice, it
was clear that these animals had significant fluid retention. Their sub-
cutaneous (0.63 ± 0.06 g, P < 0.01 versus high-fat diet) and visceral fat
content (1.60 ± 0.08 g, P < 0.01 versus high-fat diet) were virtually iden-
tical to those of mice injected with 25mg/kg intraperitoneally every 8 days.
The fluid retention was not surprising given the substantial sodium con-
tent of the vehicle given every 2 days along with the role of Na/K-ATPase
signaling in the adaptive natriuresis with salt loading (21).
Blood measurements of adiponectin
The high molecular weight form of adiponectin was determined in
serum with an ELISA assay according to the manufacturer’s protocol.
Western blot analysis
Visceral fat was pulverized in liquid nitrogen and placed in homogeni-
zation buffer. Homogenates were centrifuged, the supernatant was iso-
lated, and immunoblotting was performed. The supernatant was used
for the determination of FAS, adiponectin, PPARg, and MEST. b-Actin
was used to ensure adequate sample loading for all Western blots as
previously described, Li et al. (3) and Sodhi et al. (40).
Measurement of c-Src and ERK1/2 phosphorylation
Visceral fat and whole-cell lysates obtained from 3T3L1 adipocytes were
prepared with NP-40 buffer, and activation of c-Src and ERK1/2 was
determined as previously described by Yan et al. (28). After immuno-
blotting for phospho–c-Src and phospho-ERK1/2, the same membrane
was stripped and immunoblotted for total c-Src and total ERK1/2. Ac-
tivation of c-Src and ERK1/2 was expressed as the ratios of phospho–c-
Src/total Src and phospho-ERK1/2/total ERK1/2, respectively, with
both measurements normalized to 1.0 for the control samples.
Assessment of protein carbonylation
Visceral fat and whole-cell lysates were prepared with NP-40 buffer,
and Western blotting for protein carbonylation assay was done (24, 28).
The signal density values of control samples were normalized to 1.0
with Ponceau S staining as a loading control.
Glucose tolerance test
Glucose clearance was determined using an intraperitoneal glucose
tolerance test before termination of the experiment. Mice were fasted
for 8 hours, after which a glucose solution (2 g/kg, injected as a 10% solu-
tion) was injected into the peritoneal cavity. Samples were taken from the
tail vein at 0, 30, 60, and 120 min after glucose injection. Blood glucose
was measured using the Accutrend Sensor glucometer.
Determination of homeostasis model assessment of
insulin resistance
The homeostasis model assessment of insulin resistance (HOMA-IR) was
calculated from mouse blood using glucose and insulin concentrations
obtained after 8 hours of food withdrawal, using the following formula:
HOMA-IR = [fasting insulin (ng/ml) × fasting glucose (mM)]/22.5.
Lipid peroxidation measurement. Visceral fat lipid peroxidation
was measured as TBARS using an assay kit according to the manufac-
turer’s protocol. Visceral fat samples were homogenized in a buffer
solution containing 50 mM tris-HCl (pH 7.4) and 1.15% KCl and then
centrifuged. The supernatant was used for the assay. Data were nor-
malized to total protein and presented as micromoles per milligram of
protein.
Distribution of rhodamine B–labeled pNaKtide. For the in vitro
study, murine preadipocytes (3T3L1) were grown on glass coverslips
and treated with or without rhodamine B–labeled pNaKtide (2 mM).
At the indicated time points, the cells were fixed with cold absolute
methanol and mounted with 4′,6-diamidino-2-phenylindole (DAPI)
mounting medium (Vector Labs). Images were taken (emission read-
ings for DAPI and rhodamine B were 415 to 475 nm and 580 to 650 nm,
respectively) with a Leica SP5 TCS II equipped with coherent chame-
leon multiphoton vision II (IR) laser and analyzed by Leica LAS/AF
software. For the in vivo study, mice were injected intraperitoneally
without (as control) or with rhodamine B–labeled pNaKtide (25 mg/kg).
Three hours after injection, the mice were sacrificed, and the adipose
tissues were imaged and analyzed as described earlier.
Statistical analyses
Statistical significance between experimental groups was de-
termined by the Fisher method of analysis of multiple comparisons
(P < 0.05). For comparisons among treatment groups, the null hy-
pothesis was tested by a two-factor analysis of variance (ANOVA)
for multiple groups or unpaired t test for two groups. Data are presented
as means ± SE.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/1/9/e1500781/DC1
Fig. S1. pNaKtide distribution in 3T3L1 cells and adipose tissue.
Fig. S2. pNaKtide decreased large lipid droplets and oxidative stress and increased small lipid
droplets in 3T3L1 adipocytes.
Fig. S3. pNaKtide decreased lipid accumulation and adipogenic markers in 3T3L1 adipocytes
exposed to fructose.
Fig. S4. pNaKtide decreased lipid accumulation and adipogenic markers in 3T3L1 adipocytes
exposed to glucose oxidase.
Fig. S5. pNaKtide decreased carbonylation and phosphorylation of Src and ERK in 3T3L1
adipocytes exposed to glucose oxidase.
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